Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 323.72
NRIFF's Cash to Debt is ranked higher than
68% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. NRIFF: 323.72 )
Ranked among companies with meaningful Cash to Debt only.
NRIFF' s 10-Year Cash to Debt Range
Min: 0.02  Med: 6.00 Max: 29137.5
Current: 323.72
0.02
29137.5
Equity to Asset 0.86
NRIFF's Equity to Asset is ranked higher than
88% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NRIFF: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
NRIFF' s 10-Year Equity to Asset Range
Min: -0.42  Med: 0.75 Max: 0.99
Current: 0.86
-0.42
0.99
F-Score: 4
Z-Score: 2.95
M-Score: -3.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -108.55
NRIFF's Operating margin (%) is ranked lower than
90% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. NRIFF: -108.55 )
Ranked among companies with meaningful Operating margin (%) only.
NRIFF' s 10-Year Operating margin (%) Range
Min: -1350.37  Med: -234.50 Max: 42.55
Current: -108.55
-1350.37
42.55
Net-margin (%) 262.95
NRIFF's Net-margin (%) is ranked higher than
99% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. NRIFF: 262.95 )
Ranked among companies with meaningful Net-margin (%) only.
NRIFF' s 10-Year Net-margin (%) Range
Min: -1222.18  Med: -360.22 Max: 295.55
Current: 262.95
-1222.18
295.55
ROE (%) 80.71
NRIFF's ROE (%) is ranked higher than
97% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. NRIFF: 80.71 )
Ranked among companies with meaningful ROE (%) only.
NRIFF' s 10-Year ROE (%) Range
Min: -978.57  Med: -59.30 Max: 113.73
Current: 80.71
-978.57
113.73
ROA (%) 67.63
NRIFF's ROA (%) is ranked higher than
99% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. NRIFF: 67.63 )
Ranked among companies with meaningful ROA (%) only.
NRIFF' s 10-Year ROA (%) Range
Min: -153.07  Med: -42.14 Max: 88.96
Current: 67.63
-153.07
88.96
ROC (Joel Greenblatt) (%) 322.31
NRIFF's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. NRIFF: 322.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NRIFF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -655.33  Med: -363.06 Max: 3057.7
Current: 322.31
-655.33
3057.7
Revenue Growth (3Y)(%) -17.00
NRIFF's Revenue Growth (3Y)(%) is ranked lower than
88% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NRIFF: -17.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NRIFF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37.7  Med: -2.80 Max: 48.7
Current: -17
-37.7
48.7
» NRIFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NRIFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1.50
NRIFF's P/E(ttm) is ranked higher than
99% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. NRIFF: 1.50 )
Ranked among companies with meaningful P/E(ttm) only.
NRIFF' s 10-Year P/E(ttm) Range
Min: 0.88  Med: 10.11 Max: 207.85
Current: 1.5
0.88
207.85
PE(NRI) 1.50
NRIFF's PE(NRI) is ranked higher than
99% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. NRIFF: 1.50 )
Ranked among companies with meaningful PE(NRI) only.
NRIFF' s 10-Year PE(NRI) Range
Min: 0.88  Med: 6.45 Max: 19.64
Current: 1.5
0.88
19.64
P/B 1.20
NRIFF's P/B is ranked higher than
84% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. NRIFF: 1.20 )
Ranked among companies with meaningful P/B only.
NRIFF' s 10-Year P/B Range
Min: 0.61  Med: 2.11 Max: 41.78
Current: 1.2
0.61
41.78
P/S 4.21
NRIFF's P/S is ranked lower than
59% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. NRIFF: 4.21 )
Ranked among companies with meaningful P/S only.
NRIFF' s 10-Year P/S Range
Min: 0.77  Med: 3.20 Max: 32.5
Current: 4.21
0.77
32.5
EV-to-EBIT 0.18
NRIFF's EV-to-EBIT is ranked higher than
100% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. NRIFF: 0.18 )
Ranked among companies with meaningful EV-to-EBIT only.
NRIFF' s 10-Year EV-to-EBIT Range
Min: -12.3  Med: -2.30 Max: 8.3
Current: 0.18
-12.3
8.3
Current Ratio 6.98
NRIFF's Current Ratio is ranked higher than
84% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. NRIFF: 6.98 )
Ranked among companies with meaningful Current Ratio only.
NRIFF' s 10-Year Current Ratio Range
Min: 0.14  Med: 3.52 Max: 25.02
Current: 6.98
0.14
25.02
Quick Ratio 6.75
NRIFF's Quick Ratio is ranked higher than
85% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. NRIFF: 6.75 )
Ranked among companies with meaningful Quick Ratio only.
NRIFF' s 10-Year Quick Ratio Range
Min: 0.05  Med: 3.25 Max: 23.62
Current: 6.75
0.05
23.62
Days Inventory 79.32
NRIFF's Days Inventory is ranked higher than
67% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. NRIFF: 79.32 )
Ranked among companies with meaningful Days Inventory only.
NRIFF' s 10-Year Days Inventory Range
Min: 75.26  Med: 181.84 Max: 960.13
Current: 79.32
75.26
960.13
Days Sales Outstanding 60.66
NRIFF's Days Sales Outstanding is ranked higher than
58% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. NRIFF: 60.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRIFF' s 10-Year Days Sales Outstanding Range
Min: 19.7  Med: 73.60 Max: 419.77
Current: 60.66
19.7
419.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.12
NRIFF's Price/Net Cash is ranked higher than
95% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. NRIFF: 1.12 )
Ranked among companies with meaningful Price/Net Cash only.
NRIFF' s 10-Year Price/Net Cash Range
Min: 0.9  Med: 10.42 Max: 949.49
Current: 1.12
0.9
949.49
Price/Net Current Asset Value 1.04
NRIFF's Price/Net Current Asset Value is ranked higher than
96% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. NRIFF: 1.04 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NRIFF' s 10-Year Price/Net Current Asset Value Range
Min: 0.84  Med: 5.03 Max: 4029.9
Current: 1.04
0.84
4029.9
Price/Tangible Book 1.02
NRIFF's Price/Tangible Book is ranked higher than
85% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NRIFF: 1.02 )
Ranked among companies with meaningful Price/Tangible Book only.
NRIFF' s 10-Year Price/Tangible Book Range
Min: 0.82  Med: 4.08 Max: 1917.5
Current: 1.02
0.82
1917.5
Price/Projected FCF 3.40
NRIFF's Price/Projected FCF is ranked lower than
279% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. NRIFF: 3.40 )
Ranked among companies with meaningful Price/Projected FCF only.
NRIFF' s 10-Year Price/Projected FCF Range
Min: 1.86  Med: 3.61 Max: 6.32
Current: 3.4
1.86
6.32
Price/Median PS Value 1.13
NRIFF's Price/Median PS Value is ranked lower than
52% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. NRIFF: 1.13 )
Ranked among companies with meaningful Price/Median PS Value only.
NRIFF' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 1.69 Max: 124.8
Current: 1.13
0.28
124.8
Price/Graham Number 0.23
NRIFF's Price/Graham Number is ranked higher than
97% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. NRIFF: 0.23 )
Ranked among companies with meaningful Price/Graham Number only.
NRIFF' s 10-Year Price/Graham Number Range
Min: 0.2  Med: 0.58 Max: 1.1
Current: 0.23
0.2
1.1
Earnings Yield (Greenblatt) (%) 557.25
NRIFF's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NRIFF: 557.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NRIFF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 12.1  Med: 32.80 Max: 664.2
Current: 557.25
12.1
664.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:NRI.Canada, DLAN.Germany,
Nuvo Research, Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario. The Company is a publicly traded Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group. The TPT Group has four commercialized products, a pipeline of products at various stages of development focusing on the following therapeutic areas: pain, dermatology, central nervous system (CNS) and endocrinology and four topical and transdermal drug delivery (TTDD) platforms. The Immunology Group has two commercialized products, a development program for the treatment of allergic rhinitis and a potential immune system modulation platform. The Company has four commercialized products: Pennsaid, Pennsaid 2%, the heated lidocaine/tetracaine patch (HLT Patch, formerly known as Synera) and Pliaglis. The Company is building a portfolio of products for the treatment of pain through internal research and development (R&D) and by in-licensing and acquisition. The Company is also involved in R&D activities with WF10, a chlorite-based immune modulating drug, through Nuvo Research AG.
» More Articles for NRIFF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NRI.TO: Update on Second Quarter 2015 Financials Aug 27 2015
Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO Aug 20 2015
Nuvo Research® Announces Grant of United States Patent for Topical Onychomycosis Formulation Aug 11 2015
Nuvo Research® Announces 2015 Second Quarter Results Aug 05 2015
Nuvo Research® Provides Update on International Licensing of Pennsaid® 2% Jun 24 2015
Nuvo Research® Receives Health Canada Approval to Conduct New WF10™ Phase 2 Trial Jun 08 2015
Nuvo Research announces director election results of its Annual General Meeting May 13 2015
Nuvo Research® Announces 2015 First Quarter Results May 12 2015
Nuvo Research® Announces New WF10™ Phase 2 Trial Apr 22 2015
Nuvo Research® Announces New WF10™ Phase 2 Trial Apr 22 2015
Nuvo Research® Updates Company Strategy Apr 16 2015
Nuvo Research® Updates Company Strategy Apr 16 2015
Nuvo Research® Provides Business Update Mar 05 2015
NRI.TO: Cash Balance and Pending Phase 3 Trial with Pennsaid 2% Keep Nuvo Research Looking... Feb 20 2015
Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results Feb 19 2015
NRI.TO: WF10 Fails Phase 2 Allergic Rhinitis Study Jan 30 2015
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10™ Dec 22 2014
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and... Nov 13 2014
Nuvo Research® Announces 2014 Third Quarter Results Nov 10 2014
Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK